News

Register Now for Open Forum 4: Key Issues in TB Drug Development


25 Apr 2010
by Working Group

Open Forum 4 Banner
Open Forum 4: Key Issues in TB Drug Development
August 18-19, 2010 | Addis Ababa, Ethiopia

REGISTER NOW FOR:
Open Forum 4: Key Issues
in TB Drug Development

August 18-19, 2010 | Addis Ababa, Ethiopia

International Conference to address regulatory challenges to
TB drug development in Africa.

Don’t miss this important two-day Open Forum on August 18-19, in Addis Ababa, Ethiopia. The conference will address key issues in TB drug development, with a special focus on regulatory affairs. This upcoming event will highlight TB drug development challenges in light of new treatment advances and feature keynote addresses from thought leaders in the field of tuberculosis.

Registration is free and open now. Click here and register today

This event marks the fourth in a series of crucial meetings designed to bring together regulators, TB drug developers, and other interested stakeholders such as TB care providers, public health policy-makers, and community advocates from both major industrialized and high-burden countries. Previous meetings in the series have been held in North America, Europe, and Asia, and have been attended by hundreds of key stakeholders in TB drug development and decision-makers in regulatory processes.

With the recent announcement of the Critical Path for New TB Regimens, this upcoming meeting is one of the first forums available to discuss the regulatory implications of a new TB drug development paradigm, particularly from an African perspective. The Forum will also include sessions on the current global TB drug development portfolio, key issues in the critical path to TB drug registration, designing pivotal trials, and conducting registration trials in high TB burden countries.

This meeting is sponsored by the TB Alliance, the Bill & Melinda Gates Foundation, the Stop TB Working Group on New TB Drugs, and Treatment Action Group (TAG).

Supported in part by unrestricted educational grants from AstraZeneca, Bayer Schering Pharma, Celgene, GlaxoSmithKline, Novartis International AG, Pfizer, sanofi-aventis, and Tibotec.

Accommodations and travel must be paid for by meeting attendees

> Download a list of local accommodations and rates [.pdf – 68k] > Download a map of the area [.pdf – 904k]

More News
30 Mar 2021
Médecins Sans Frontières (MSF) published a press release on World TB Day 2021 announcing their clinical trial, TB-Practecal , investigating novel treatment for MDR-TB has stopped enrolling earlier than originally planned due to promising results. The trial's independent data safety and monitoring...
3 Feb 2021
Last week, the World Health Organization (WHO) held a consultation to discuss the definition of extensively drug resistant (XDR) tuberculosis. The meeting was held to discuss novel treatment regimens and diagnostics for drug-resistant TB and determine its impact on the definition of XDR-TB. The...
10 Dec 2020
The Stop TB Partnership Working Group on New TB Vaccines (WGNV), Working Group on New TB Drugs (WGND), and New Diagnostics Working Group (NDWG) are developing an online course specifically designed for advocates and affected communities to provide a base of knowledge in TB research and to generate...